[Skip to Content]
[Skip to Content Landing]
June 1966

Hydroxymethylprogesterone: An Anti-Inflammatory Steroid Without Apparent Effect on Intraocular Pressure

Author Affiliations

Bethesda, Md
From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, Public Health Service, US Department of Health, Education and Welfare, Bethesda, Md.

Arch Ophthalmol. 1966;75(6):783-787. doi:10.1001/archopht.1966.00970050785014

It has been incontestably demonstrated that topical administration of certain adrenocorticosteroids produces in some individuals an increase in intraocular pressure.1-3 This fact raises immediate practical and theoretical considerations. Were it possible to find a drug with anti-inflammatory activity, yet free from intraocular pressure-increasing effect, we should have both a beneficial therapeutic agent and a valuable investigative tool. This paper reports initial findings in the study of such a medication.

Methods  Medrysone (hydroxymethylprogesterone), 1.0%, was the drug studied. Chlorbutanol was the preservative and polyvinyl alcohol the primary constituent of the vehicle.Subjects consisted of seven normal controls, 15 patients with open-angle glaucoma, and one patient with keratoconjunctivitis. Of the 23 subjects, nine were female. The normal controls were college students with no evidence of glaucoma and with negative family histories. Medrysone was instilled in one eye of each volunteer and dexamethasone, 0.1%, in the other. Of the glaucoma patients, aged